(Q36931609)

17 August 2017

1 reference

title

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders (English)

1 reference

17 August 2017

Michael T Heneka

1

1 reference

PubMed ID

17805244

17 August 2017

Gary E Landreth

series ordinal

2

1 reference

PubMed ID

17805244

17 August 2017

Michael Hüll

series ordinal

3

1 reference

17 August 2017

1 September 2007

1 reference

Nature Clinical Practice Neurology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

9

1 reference

17 August 2017

496-504

1 reference

Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

Emerging roles of PPARs in inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inflammatory processes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

The many roles of chemokines and chemokine receptors in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Post-ischemic inflammation: molecular mechanisms and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Inflammation following stroke.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Altered PPARgamma expression and activation after transient focal ischemia in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

PPAR-gamma: therapeutic target for ischemic stroke

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Effects of thiazolidinediones on stroke recovery: a case-matched controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0586

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0586

1 reference

17 August 2017

1 reference

PubMed ID

17805244